contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


biostock-herantis-stock-rallies-on-strong-biomarker-data-paving-the-way-for-phase-ii

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Herantis now has a very substantial dataset at its disposal regarding these biomarkers, and its more detailed analysis will take some time. What I personally paid attention to in that presentation was that the data also showed changes in blood samples (as I recall, this was related to mitochondrial DNA damage, which likely served as a proxy for oxidative stress). Based on the drug’s distribution, it is understandable that it also has effects outside the central nervous system, but now there is biological evidence for that as well. The structure of HER-096 is based on the active domain of CDNF, which interacts with GRP78. The effect of CDNF itself might be more limited to, for example, neurons, meaning HER-096 could potentially have broader effects than CDNF would. What makes this interesting is that this active domain is conserved between CDNF and MANF. This raises the question: to what extent can HER-096 replicate the effects of MANF in the body? MANF is known to have a protective effect on pancreatic beta cells, meaning that in an optimal scenario, HER-096 could be useful in the treatment of diabetes, for example. But perhaps even more interesting (yet more speculative) is MANF’s link to parabiosis (parabiosis is, by the way, quite a “mad scientist” experimental setup…), which could point to an even broader potential for HER-096, provided that the GRP78 interaction is sufficient to replicate MANF’s effect. Anyway, these data will likely provide hints regarding these other potential effects of HER-096 once they can be analyzed in sufficient depth.

Looking at that webcast starting from 38:20, the CFO is certainly struggling to hold back a smile. I wonder if they’re just happy that the webinar is coming to an end…

Antti Siltanen has published a new company report on Herantis Pharma.  Herantis released new results from its biomarker analysis. The results relate to the Phase I clinical safety and tolerability study of the HER-096 drug candidate, which included an analysis of biomarkers. According to the results, the candidate shows biological activity in Parkinson’s patients. In practice, the reported positive results impact the planning of the next research phase and potentially provide leverage in partnership negotiations with a larger pharmaceutical company. In our view, Herantis’s big picture remains unchanged following the results, so we reiterate our target price of 2.5 euros. Due to the rise in share price, the risk-reward ratio has weakened, which is why we are lowering our recommendation to Reduce (prev. Accumulate).                   Inderes              Herantis: Merkkiaineanalyysi viimeisteli onnistuneen vaiheen I - Inderes    Herantis julkaisi myönteisiä tuloksia merkkiaineanalyysistä.

Things are progressing. Herantis reports that “Phase 1b biomarker data shows a clear biological response to HER-096 in patients with Parkinson’s disease.” Therefore, mechanistic evidence of the drug’s effect on the disease is being obtained, which will be important for future marketing authorizations. However, Herantis also states that the data will be submitted to scientific journals, which means the significance of the results now obtained will remain for the scientific community to assess through peer review. Those publications take several months. If one aims for accelerated approval (AA), for example via a randomized Phase 2 trial, there should be strong evidence that a specific biomarker predicts clinical benefit, unless clinical benefit—i.e., symptom relief—has not yet been observed due to the slow-progressing nature of the disease. It may be that Herantis is only now building the scientific case for this and may be able to prove through various phases that this is indeed the case. Although diseases and mechanisms cannot be fully compared, among neurological diseases, AA has been granted for tofersen in ALS based on a biomarker and similarly in Alzheimer’s based on plaque reduction; this has caused some controversy, and this AA pathway is currently uncertain. From a partnering perspective, the data now obtained is encouraging, but we will see what it is sufficient for. Would biomarker evidence be enough for FDA/EMA Fast Track status after peer review, if the evidence proves to be strong?

Here are Siltanen’s comments on this latest news.  Herantis Pharma released a press release on Wednesday evening regarding the biomarker analysis of its Phase Ib study. According to the results, the HER-096 drug candidate affects biological pathways in the central nervous system that are essential for Parkinson’s disease. The positive results support the advancement of drug development to preliminary efficacy studies (clinical Phase II), assist in the design of the Phase II study, and contribute to the company’s partnership negotiations to fund the upcoming study. A briefing on the results will be held today at 12:00, which can be followed here. Preliminarily, we do not expect the results to affect our forecasts, as we have already considered the progression of development to the next phase to be quite likely.                   Inderes              Herantiksen tuore analyysi kertoo HER-096:n aktiivisuudesta keskushermostossa...    Herantis julkaisi tietoja vaiheen Ib -tutkimuksen merkkiaineanalyysistä.

100 percent so, gratefull feelings amomg many PD patients and Michael J Fox foundation💘

It was nice to read the excellent news. I wouldn’t be surprised if there were a takeover bid for Herantis in the coming months, as it is a “small” single-asset company. The only question then is at what price it would go. The board likely has some exit price in mind…

Herantis Pharma

Herantis Pharma delivers a sign of strength that sends the stock soaring. New data from the company's phase Ib trial shows that the drug candidate HER-096 is not only safe but also elicits a...

<div class="mfn-preamble"><p><strong>Herantis Pharma delivers a sign of strength that sends the stock soaring. New data from the company's phase Ib trial shows that the drug candidate HER-096 is not only safe but also elicits a clear biological response in patients with Parkinson's disease. The results are described as a crucial milestone that significantly de-risks the project ahead of the upcoming phase II trial. BioStock reached out to CEO Antti Vuolanto to dig deeper.</strong></p></div><div class="mfn-body"><p>Read the full article at&nbsp;<a rel="noopener" href="https://www.biostock.se/en/">biostock.se</a>:<br><a rel="noopener" href="https://biostock.se/en/2026/01/herantis-aktie-rusar-pa-starka-biomarkordata-banar-vag-for-fas-ii/">https://biostock.se/en/2026/01/herantis-aktie-rusar-pa-starka-biomarkordata-banar-vag-for-fas-ii/</a><br>This is a press release from<strong>&nbsp;BioStock - Connecting Innovation &amp; Capital</strong>.&nbsp;<a rel="noopener" href="https://www.biostock.se/">https://www.biostock.se</a></p></div><div class="mfn-footer mfn-about mfn-e63cb96431c5"><p><strong class="mfn-heading-1">Follow BioStock</strong><br>Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at <a rel="noopener" href="https://www.biostock.se/newsletter">https://www.biostock.se/newsletter</a>&nbsp;<br>Follow BioStock on social media: <a rel="noopener" href="https://www.linkedin.com/company/biostock/">LinkedIn</a> and <a rel="noopener" href="https://www.facebook.com/biostock.se%22%20/t%20%22_blank">Facebook</a>! &nbsp;<br>&nbsp;<br><strong>About BioStock</strong>&nbsp;<br>BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.&nbsp;&nbsp;<br>BioStock – Connecting Innovation &amp; Capital.&nbsp;</p></div>